IP Library Granted Patent US 11,965,173
Granted Patent B2
US 11,965,173 · App. 16/772,216 · Granted Apr 23, 2024

Plasmid system

Inventors: Martin Pulé (London, GB); Paulo Fernandes (London, GB); Hanna Kymalainen (London, GB); Ekaterini Kotsopoulou (London, GB)
Assignee: AUTOLUS LIMITED
C12N15/86C12N15/85C12N2740/13022C12N2740/13043C12N2740/13052C12N2800/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,965,173
App. No.
16/772,216
Granted
Apr 23, 2024
Kind
B2
Abstract

There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins; b. an envelope plasmid comprising a second nucleotide sequence encoding an Env protein; c. a genome plasmid comprising a third nucleotide sequence encoding a retroviral genome, wherein the first nucleotide sequence is codon-shuffled to remove any significant regions of homology with the third nucleotide sequence; and wherein the second nucleotide sequence is codon-optimised for expression in the producer cell.

Claims (14)

1. A plasmid system for transfection into a cell to create a producer cell, the system comprising:

a) a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins,

b) an envelope plasmid comprising a second nucleotide sequence encoding an Env protein,

c) a genome plasmid comprising a third nucleotide sequence comprising a retroviral genome,

wherein the first nucleotide sequence comprises the sequence selected from SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, and

wherein the second nucleotide sequence is codon-optimized for expression in the producer cell.

2. The system of claim 1 , wherein the second nucleotide sequence comprises the sequence selected from SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11.

3. The system of claim 1 , wherein the Env protein is RD114 Envelope protein.

4. The system of claim 3 , wherein the codon adaptation index (CAI) of the second nucleotide sequence is at least 0.75.

5. The system of claim 1 , wherein the genome plasmid further comprises a nucleotide of interest (NOI).

6. The system of claim 1 , wherein genome plasmid comprises a packaging signal, which has homology with a portion of the wildtype MLV nucleotide sequence encoding Gag and/or Pol polyprotein(s).

7. A producer cell capable of producing retroviral vectors, comprising the plasma system of claim 1 .

8. A nucleotide sequence encoding MLV-derived Gag and Pol poly-proteins comprising the sequence selected from: SEQ ID NO: 1 to SEQ ID NO: 3.

9. A nucleotide sequence encoding Env protein comprising the sequence selected from: SEQ ID NO: 5 to SEQ ID NO: 7 and SEQ ID NO: 9 to 11.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: KYMALAINEN, HANNA; FERNANDES, PAULO; PULÉ, MARTIN; KOTSOPOULOU, EKATERNIN
To: AUTOLUS LIMITED
Reel/Frame 052921/0643 →
Priority Claims (1)
GB 1720948 · Dec 15, 2017 · national
Continuity (1)
Related Publication 20230242937A1 · Aug 3, 2023